Search Results

[Vernal keratoconjunctivitis (VKC) successfully treated with omalizumab].

• Authors : Mozo Cuadrado M; Ophtalmologie, Complejo Hospitalario de Navarra, Pamplona, Espagne. Electronic address: .; Orive Bañuelos A

Subjects: Conjunctivitis, Allergic/Conjunctivitis, Allergic/Conjunctivitis, Allergic/*drug therapy ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use; Adolescent

• Source: Journal francais d'ophtalmologie [J Fr Ophtalmol] 2020 Jun; Vol. 43 (6), pp. e193-e195. Date of Electronic Publication: 2020 May 04.Publisher: Masson Country of Publication: France NLM ID: 7804128 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1773-0597

Record details

[The efficacy of omalizumab in the treatment of chronic rhinosinusitis with nasal polyps: a discussion of 2 refractory cases].

• Authors : Jandus P; Service d'allergologie et immunologie clinique, HUG, 1211 Genève 14.; Harr T

Subjects: Nasal Polyps/Nasal Polyps/Nasal Polyps/*complications ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use ; Rhinitis/Rhinitis/Rhinitis/*complications

• Source: Revue medicale suisse [Rev Med Suisse] 2019 Oct 02; Vol. 15 (665), pp. 1748-1751.Publisher: Médecine et Hygiène Country of Publication: Switzerland NLM ID: 101219148 Publication Model: Print Cited Medium: Print ISSN:

Record details

[Omalizumab for severe vernal keratoconjunctivitis].

• Authors : Callet M; Service d'ophtalmologie, CHU Nord Chemin des Bourrely, 13015 Marseille, France. Electronic address: .; Stolowy N

Subjects: Anti-Allergic Agents/Anti-Allergic Agents/Anti-Allergic Agents/*therapeutic use ; Conjunctivitis, Allergic/Conjunctivitis, Allergic/Conjunctivitis, Allergic/*drug therapy ; Drug Resistance/Drug Resistance/Drug Resistance/*drug effects

• Source: Journal francais d'ophtalmologie [J Fr Ophtalmol] 2018 Dec; Vol. 41 (10), pp. e499-e500. Date of Electronic Publication: 2018 Nov 23.Publisher: Masson Country of Publication: France NLM ID: 7804128 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1773-0597

Record details

[Omalizumab and allergen immunotherapy: A clinical report and review of the literature].

• Authors : Carrier C; Unité d'allergologie, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, université de Montpellier, CHU de Montpellier, 371, avenue du Doyen-Gaston-Giraud, 34090 Montpellier, France.; Demoly P

Subjects: Desensitization, Immunologic*; Anti-Asthmatic Agents/Anti-Asthmatic Agents/Anti-Asthmatic Agents/*therapeutic use ; Asthma/Asthma/Asthma/*therapy

• Source: Revue des maladies respiratoires [Rev Mal Respir] 2019 Feb; Vol. 36 (2), pp. 191-196. Date of Electronic Publication: 2018 Nov 03.Publisher: Elsevier-Masson Country of Publication: France NLM ID: 8408032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Omalizumab for the treatment of chronic urticaria: Real-life findings].

• Authors : Hamelin A; Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France. Electronic address: .; Amsler E

Subjects: Anti-Allergic Agents/Anti-Allergic Agents/Anti-Allergic Agents/*therapeutic use ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use ; Urticaria/Urticaria/Urticaria/*drug therapy

• Source: Annales de dermatologie et de venereologie [Ann Dermatol Venereol] 2019 Jan; Vol. 146 (1), pp. 9-18. Date of Electronic Publication: 2019 Jan 09.Publisher: Masson Country of Publication: France NLM ID: 7702013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0151-9638

Record details

[Omalizumab: Beyond anti-IgE properties].

• Authors : Perotin JM; Service des maladies respiratoires, Inserm UMRS 903, centre hospitalier universitaire, 45, rue Cognacq-Jay, 51100 Reims, France. Electronic address: .; Barnig C

Subjects: Antibodies, Anti-Idiotypic/Antibodies, Anti-Idiotypic/Antibodies, Anti-Idiotypic/*therapeutic use ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use ; Respiratory Hypersensitivity/Respiratory Hypersensitivity/Respiratory Hypersensitivity/*drug therapy

• Source: Revue des maladies respiratoires [Rev Mal Respir] 2017 Feb; Vol. 34 (2), pp. 121-133. Date of Electronic Publication: 2017 Feb 08.Publisher: Elsevier-Masson Country of Publication: France NLM ID: 8408032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].

• Authors : Romand P; Service de pneumologie, hôpital Alpes-Léman, 558, route de Findrol, 74130 Contamine-sur-Arve, France. Electronic address: .; Kelkel E

Subjects: Anti-Asthmatic Agents/Anti-Asthmatic Agents/Anti-Asthmatic Agents/*therapeutic use ; Asthma/Asthma/Asthma/*drug therapy ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use

• Source: Revue des maladies respiratoires [Rev Mal Respir] 2016 May; Vol. 33 (5), pp. 397-400. Date of Electronic Publication: 2015 Sep 04.Publisher: Elsevier-Masson Country of Publication: France NLM ID: 8408032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Omalizumab: What have we learned after ten years of prescription?].

• Authors : Pradère P; Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.; Garcia G

Subjects: Drug Prescriptions*/Drug Prescriptions*/Drug Prescriptions*/statistics & numerical data; Asthma/Asthma/Asthma/*drug therapy ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use

• Source: Revue des maladies respiratoires [Rev Mal Respir] 2016 Feb; Vol. 33 (2), pp. 117-27. Date of Electronic Publication: 2015 Sep 04.Publisher: Elsevier-Masson Country of Publication: France NLM ID: 8408032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

[Patients in the IDEAL cohort: A snapshot of severe asthma in France].

• Authors : Taillé C; Service de pneumologie, centre de référence constitutif des maladies pulmonaires rares, DHU FIRE, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France; Inserm U1152, université Paris-Diderot, Labex Inflamex, 75018 Paris, France. Electronic address: .

Subjects: Anti-Asthmatic Agents/Anti-Asthmatic Agents/Anti-Asthmatic Agents/*therapeutic use ; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Asthma/Asthma/Asthma/*drug therapy

• Source: Revue des maladies respiratoires [Rev Mal Respir] 2019 Feb; Vol. 36 (2), pp. 179-190. Date of Electronic Publication: 2018 Nov 11.Publisher: Elsevier-Masson Country of Publication: France NLM ID: 8408032 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Effet de l'omalizumab dans l'aspergillose broncho-pulmonaire allergique : à propos de 10 patients asthmatiques.

• Authors : Melscoet, L.; Khayath, N.; de Blay, F.

• Source: Revue Francaise d'Allergologie; Jun2019, Vol. 59 Issue 4, p316-323, 8p

Record details